Patterns of care in relapsed/refractory multiple myeloma in China: a real-world physician survey study

Multiple Myeloma (MM) is a complex hematologic malignancy with a rapidly evolving therapeutic landscape. Real-world data on treatment regimen use beyond the first line in China are limited.

We analyzed data from the CancerMPact Treatment Architecture database, based on a 2024 survey of 120 Chinese physicians regarding management and treatment durations for relapsed/refractory MM. Descriptive statistics summarized regimen selection and duration across second and later lines.

Substantial heterogeneity in regimen selection was observed, with no single regimen used in more than 10% of patients across all treatment lines. In second line, 66.3% of patients received a bortezomib-based, daratumumab-based, or daratumumab plus bortezomib-based regimen. Common second-line regimens and time of utilization included carfilzomib, pomalidomide, dexamethasone (9.6%; 9.2 months), daratumumab, bortezomib, dexamethasone (9.0%; 8.1 months), and daratumumab, bortezomib, lenalidomide, dexamethasone (7.6%; 7.7 months). In third line, top regimens were carfilzomib, pomalidomide, dexamethasone (9.0%; 7.3 months), daratumumab, carfilzomib, dexamethasone (8.2%; 8.3 months), and daratumumab, bortezomib, lenalidomide, dexamethasone (7.1%; 8.1 months). Novel agents and chimeric antigen receptor (CAR)-T cell therapies saw increased use in later lines.

Real-world management of relapsed/refractory MM in China is highly variable. These findings highlight the necessity for ongoing research and evidence-based guidelines to optimize patient outcomes.